These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8859617)

  • 21. Single-dose dexamethasone paclitaxel premedication.
    Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
    Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
    Tsavaris N; Polyzos A; Kosmas C; Giannikos L; Gogas J
    Cancer Chemother Pharmacol; 1997; 40(4):353-7. PubMed ID: 9225955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
    Ohtsu T; Sasaki Y; Tamura T; Miyata Y; Nakanomyo H; Nishiwaki Y; Saijo N
    Clin Cancer Res; 1995 Jun; 1(6):599-606. PubMed ID: 9816021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taxoids: new weapons against cancer.
    Nicolaou KC; Guy RK; Potier P
    Sci Am; 1996 Jun; 274(6):94-8. PubMed ID: 8643952
    [No Abstract]   [Full Text] [Related]  

  • 25. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Paclitaxel].
    Díaz M; Campanero MA
    Rev Med Univ Navarra; 1996; 40(3):43-51. PubMed ID: 9499826
    [No Abstract]   [Full Text] [Related]  

  • 27. Paclitaxel-induced myocardial infarction in a case of carcinoma ovary.
    Londhey VA; Parikh FS
    J Assoc Physicians India; 2009 Apr; 57():342-3. PubMed ID: 19702043
    [No Abstract]   [Full Text] [Related]  

  • 28. Histamine-2 (H
    Foreman E; Polwart C; Walker A; Chambers P
    Br J Clin Pharmacol; 2022 Sep; 88(9):4191-4198. PubMed ID: 35470452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
    Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
    Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nail toxicity associated with paclitaxel treatment for ovarian cancer.
    Swenson KK; Bell EM; Nissen J
    Oncol Nurs Forum; 2013 Jan; 40(1):17-9. PubMed ID: 23269765
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
    Lehoczky O; Bagaméri A; Udvary J; Pulay T
    J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
    [No Abstract]   [Full Text] [Related]  

  • 32. Interaction between paclitaxel and warfarin.
    Thompson ME; Highley MS
    Ann Oncol; 2003 Mar; 14(3):500. PubMed ID: 12598362
    [No Abstract]   [Full Text] [Related]  

  • 33. Localized toxic erythema of chemotherapy during treatment with paclitaxel.
    Spicknall KE; Mutasim DF
    Int J Dermatol; 2014 Jan; 53(1):e3-5. PubMed ID: 23451872
    [No Abstract]   [Full Text] [Related]  

  • 34. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
    Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
    Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scleroderma induced by paclitaxel.
    Pedersen JV; Jensen S; Krarup-Hansen A; Riis L
    Acta Oncol; 2010 Aug; 49(6):866-8. PubMed ID: 20446892
    [No Abstract]   [Full Text] [Related]  

  • 36. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL; Kossoff E
    Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
    Cormio G; Di Vagno G; Melilli GA; Cazzolla A; Di Gesù G; Carriero C; Cramarossa D; Loverro G; Selvaggi L
    J Chemother; 1999 Oct; 11(5):407-9. PubMed ID: 10632389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
    Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.